1. Home
  2. ELEV

as 06-27-2025 1:31pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.

Founded: 2019 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 22.8M IPO Year: 2021
Target Price: $1.77 AVG Volume (30 days): 2.0M
Analyst Decision: Hold Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.81 EPS Growth: N/A
52 Week Low/High: $0.22 - $3.28 Next Earning Date: 08-05-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

ELEV Daily Stock ML Predictions

Share on Social Networks: